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Background In anticoagulated patients, variations in genes responsible for warfarin activity account for half of the >10-fold individual difference in 
drug response. However, these studies have not controlled for medical comorbidities, compliance, drug interactions and vitamin K intake.
Methods In this prospective study of warfarin response, subjects were genotyped for CYP2C9 (*2, 3, 4, 5, 6, 11, 13), VKORC1 (g.-1639G>A), and 
CYP4F2 (p.V433M). Dietary vitamin K was limited to 90-120 μg/day. Those on interacting medications excluded. Drug was administered until 
international normalized ratio (INR) reached >2.0. Time to target INR and return to baseline after warfarin withdrawal was compared between 
genetic groups using a log-rank test.
Results The mean age was 34 years. INR reached >2.0 within 14 days in 21 of 22 patients. Time to target INR was 4.0±0.7 days in CYP2C9 
variants versus 8.0±1.0 days in wild-type (p=0.02). INR returned to baseline in 3.2±1.6 days. After adjusting for age, gender and body mass index, 
CYP2C9 genotype accounted for a substantial proportion of the variability in warfarin response(R2=0.43). VKORC1 and CYP4F2 genotypes had 
considerably smaller effects (p=NS).
Conclusion In subjects with no comorbid conditions, taking no interacting medications, on a fixed vitamin K diet, variation in CYP2C9 genotype 
was associated with significantly more rapid warfarin response. This study demonstrates the magnitude of the impact of genetic variation on the 
anticoagulant response to warfarin. 
